| scholarly article | Q13442814 |
| P2093 | author name string | Miller P | |
| Stein CA | |||
| Lebedeva I | |||
| Takle GB | |||
| Benimetskaya L | |||
| Vilenchik M | |||
| P2860 | cites work | Tumor localizers: porphyrins and related compounds (unusual metalloporphyrins XXIII) | Q34008330 |
| Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? | Q34299285 | ||
| Physicochemical properties of phosphorothioate oligodeoxynucleotides | Q36000544 | ||
| Mechanism of oligonucleotide release from cationic liposomes | Q37255679 | ||
| A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. | Q38344289 | ||
| Elucidation of gene function using C-5 propyne antisense oligonucleotides | Q38353215 | ||
| Potent and selective inhibition of gene expression by an antisense heptanucleotide | Q38355679 | ||
| Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus | Q39723515 | ||
| Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures | Q40420208 | ||
| Intercalative and nonintercalative binding of large cationic porphyrin ligands to polynucleotides | Q40493485 | ||
| Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid | Q45868044 | ||
| Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase | Q46110468 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5310-5317 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides | |
| P478 | volume | 26 |
| Q49202700 | (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1. |
| Q37793789 | A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene |
| Q37446015 | Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme |
| Q34107762 | Antisense cancer therapy: the state of the science |
| Q34619214 | Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme. |
| Q34089134 | Controlling the mitochondrial gatekeeper for effective chemotherapy |
| Q34047360 | Delivery systems for antisense oligonucleotides |
| Q34077630 | Down-regulation of EBV-LMP1 radio-sensitizes nasal pharyngeal carcinoma cells via NF-κB regulated ATM expression |
| Q50884730 | Drop-Coating Deposition Raman (DCDR) Spectroscopy as a Tool for Membrane Interaction Studies: Liposome-Porphyrin Complex. |
| Q40440279 | Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis |
| Q35180357 | Effect of overall charge and charge distribution on cellular uptake, distribution and phototoxicity of cationic porphyrins in HEp2 cells |
| Q73323687 | Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex |
| Q59813664 | Interactions Between Spermine-Derivatized Tentacle Porphyrins and The Human Telomeric DNA G-Quadruplex |
| Q54157081 | Keeping the biotechnology of antisense in context. |
| Q36124734 | Oligonucleotides and polyribonucleotides: a review of antiviral activity |
| Q58481592 | Study of Cellular Uptake of Modified Oligonucleotides by Using Time-Resolved Microspectrofluorimetry and Florescence Imaging |
| Q34244756 | Therapeutic RNA manipulation in liver disease. |
| Q33916104 | Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments |
| Q34518719 | Vehicles for oligonucleotide delivery to tumours |
Search more.